Premium
Decline in circulating viral and human tumor markers after resection of head and neck carcinoma
Author(s) -
Lopez Erin M.,
Tanner April Michelle,
Du Eugenie,
Patel Samip N.,
Weiss Jared,
Weissler Mark C.,
Hackman Trevor,
Gupta Gaorav P.,
Zevallos Jose,
Elmore Sandra,
Betancourt Renee,
Thorne Leigh,
Sheth Siddharth,
Gulley Margaret L.
Publication year - 2021
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.26444
Subject(s) - head and neck cancer , head and neck squamous cell carcinoma , cancer , virus , genome , carcinoma , gene , biology , helicobacter pylori , human genome , mutation , cancer research , virology , medicine , pathology , genetics
Background DNA sequencing panels can simultaneously quantify human and viral tumor markers in blood. We explored changes in levels of plasma tumor markers following surgical resection of head and neck carcinoma. Methods In preresection and postresection plasmas, targeted DNA sequencing quantified variants in 28 human cancer genes and levels of oncogenic pathogens (human papillomavirus [HPV], Epstein‐Barr virus [EBV], Helicobacter pylori ) from 21 patients with head and neck squamous cell carcinoma. Results Preresection, 11 of 21 patients (52%) had detectable tumor markers in plasma, most commonly TP53 mutation or HPV genome. Several days postresection, levels fell to undetectable in 8 of 10 evaluable patients, while two high‐stage patients retained circulating tumor markers. Conclusions Modern sequencing technology can simultaneously quantify human gene variants and oncogenic viral genomes in plasma. Falling levels of cancer‐specific markers upon resection can help identify viral and human markers to track at subsequent timepoints as a means to evaluate efficacy of interventions.